Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

World Journal of Gastroenterology

Volumn 12, Issue 18, 2006, Pages 3114-3118

  Zhou, Jian ^a   Fan, Jia ^a   Wang, Zheng ^a   Wu, Zhi Quan ^a   Qiu, Shuang Jian ^a   Huang, Xiao Wu ^a   Yu, Yao ^a   Sun, Jian ^a   Xiao, Yong Sheng ^a   He, Yi Feng ^a   Wang, Yu Qi ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Orthotopic liver transplantation; Sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SUBSTITUTION; ECHOGRAPHY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MALE; METASTASIS POTENTIAL; MOUTH ULCER; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; THROMBOCYTOPENIA;

EID: 33744506402     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i19.3114     Document Type: Article

References (23)

1. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442
2. Lam P, Yoshida A, Brown K, Abouljoud M, Bajjoka I, Dagher F, Moonka DK. The efficacy and limitations of sirolimus; conversion in liver transplant patients who develop renal dysfunction on calcineurin inhibitors. Dig Dis Sci 2004; 49: 1029-1035
3. Sharif M. Mitogenic signaling by substance P and bombesin-like neuropeptide receptors in astrocytic/glial brain tumor-derived cell lines. Int J Oncol 1998; 12: 273-286
4. Mousses S, Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, Pretlow T, Elkahloun AG, Trepel JB, Kallioniemi OP. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001; 20: 6718-6723
5. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311
6. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours. 6th Edition. Wiley-Liss, New York, 2002
7. Lawen J, Keough-Ryan T, Clase C, Kiberd B. Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study. Transplant Proc 2001; 33: 3223-3225
8. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001; 4: 378-391
9. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762
10. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774
11. Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510-513
12. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534
13. Vivarelli M, Bellusci R, Cucchetti A, Cavrini G, De Ruvo N, Aden AA, La Barba G, Brillanti S, Cavallari A. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746-1751
14. Nabel GJ. A transformed view of cyclosporine. Nature 1999; 397: 471-472
15. Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11: 1420-1425
16. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, Silberstein LE, Nowell PC, Schuler W, Shaw LM, Wasik MA. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97: 4285-4290
17. Zhou J, Fan J, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Wang Z, Sun J, Xiao YS, He YF, Yang GH, Song K, Yuan Z, Wang YQ, Tang ZY. Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China. Chin Med J (Engl) 2005; 118: 654-659
18. Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505-509
19. McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701-708
20. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59-66
21. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, Klintmalm GB. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939
22. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003; 9: 1079-1085
23. Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2063; 9: 463-468